International Registry Tracking CytoSorb Device Use in Critically Ill Patients Observational Study on CytoSorb in Critical Care Settings

What this Trial Is About

This observational registry studies the use of the CytoSorb device, a sorbent hemoperfusion system, in real-world critical care settings for patients with serious conditions such as septic shock, acute respiratory distress syndrome, trauma, and other life-threatening illnesses. The goal is to create a comprehensive data repository and reporting system to monitor and improve patient care quality when using this device in intensive care units. Participants will be those who have planned or actual use of the CytoSorb 300 mL device. The study collects data on the devices use without assigning specific treatments, serving as a scientific resource to evaluate outcomes like ICU and hospital mortality. This registry includes patients receiving the device in various critical care scenarios, excluding certain uses like antithrombotic removal or intraoperative cardiac surgery applications. During the study, data about patient outcomes through ICU discharge or hospital discharge will be collected and analyzed, typically over an average of 7 to 14 days. This includes monitoring ICU mortality and in-hospital mortality. The registry aims to support ongoing assessment of the devices use by gathering real-world patient information over time to help improve care practices in critical care environments.

CytOSorb TreatMent Of Critically Ill PatientS Registry